21.23
1.17 (5.83%)
| Previous Close | 20.06 |
| Open | 20.20 |
| Volume | 522,970 |
| Avg. Volume (3M) | 677,127 |
| Market Cap | 1,087,323,008 |
| Price / Earnings (Forward) | 94.34 |
| Price / Sales | 2.65 |
| Price / Book | 3.41 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2026 |
| Profit Margin | 17.92% |
| Operating Margin (TTM) | -9.46% |
| Diluted EPS (TTM) | 1.12 |
| Quarterly Revenue Growth (YOY) | 17.50% |
| Total Debt/Equity (MRQ) | 7.98% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | 26.78 M |
| Levered Free Cash Flow (TTM) | 29.89 M |
| Return on Assets (TTM) | -5.20% |
| Return on Equity (TTM) | 19.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | CareDx, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.60 |
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 3.22% |
| % Held by Institutions | 99.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 26.00 (BTIG, 22.47%) | Buy |
| Median | 23.50 (10.69%) | |
| Low | 21.00 (Wells Fargo, -1.08%) | Hold |
| Average | 23.50 (10.69%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 18.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 26 Feb 2026 | 26.00 (22.47%) | Buy | 18.82 |
| Wells Fargo | 25 Feb 2026 | 21.00 (-1.08%) | Hold | 18.46 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KENNEDY KEITH | 21.29 | - | 24,134 | 513,813 |
| Aggregate Net Quantity | 24,134 | |||
| Aggregate Net Value ($) | 513,813 | |||
| Aggregate Avg. Buy ($) | 21.29 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KENNEDY KEITH | Officer | 20 Apr 2026 | Acquired (+) | 24,134 | 21.29 | 513,813 |
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |